Page 1

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email!

Juvenile Idiopathic Arthritis (JIA): KOL insights on treatment practices and unmet needs Published on October 2011

Report Summary Sociable Pharma conducted in-depth primary research in the US and across Europe with seven key opinion leaders in juvenile idiopathic arthritis (JIA) to understand how therapy use will change in the future. A key theme in our research is the management and implementation of 'step-up' treatment strategies to optimize the timing of effective forms of therapy. Our view is that this is the major macro-trend that will alter treatment strategy, generating new treatment challenges and presenting opportunities for current and future market players.

Table of Content Executive Summary Scope of Analysis & Methodology Current Treatment practice Synthetic DMARDs Anti-TNF therapies Anti-interleukins Anti-CD20 antibodies Other biologics Corticosteroids NSAIDs Treatment Challenges / Unmet Needs Juvenile Idiopathic Arthritis Treatment Map Companies Mentioned Sanofi Pfizer Barr Sellec Chemicals Janssen Biotech MSD Abbott UCB Pharma Swedish Orphan Roche Novartis Roche Genentech Bristol-Myers Squibb

Juvenile Idiopathic Arthritis (JIA): KOL insights on treatment practices and unmet needs (From Issuu)

Page 1/3


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: ƒ ƒ

Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93

If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information Please verify that the product information is correct and select the format(s) you require. Juvenile Idiopathic Arthritis (JIA): KOL insights on treatment practices and unmet needs

Product Formats Please select the product formats and the quantity you require. Department License--USD 2 795.00

Quantity: _____

Corporate License--USD 5 590.00

Quantity: _____

Contact Information Please enter all the information below in BLOCK CAPITALS

Title:

Mr

Mrs

Dr

Miss

Ms

Prof

First Name:

_____________________________ Last Name: __________________________________

Email Address:

__________________________________________________________________________

Job Title:

__________________________________________________________________________

Organization:

__________________________________________________________________________

Address:

__________________________________________________________________________

City:

__________________________________________________________________________

Postal / Zip Code:

__________________________________________________________________________

Country:

__________________________________________________________________________

Phone Number:

__________________________________________________________________________

Fax Number:

__________________________________________________________________________

Juvenile Idiopathic Arthritis (JIA): KOL insights on treatment practices and unmet needs (From Issuu)

Page 2/3


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card

Card Number: ______________________________________________

Expiry Date

__________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer

Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check

UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms

Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56

ƒ ƒ

Asia, Oceania and America : + 1 (805) 617 17 93

Juvenile Idiopathic Arthritis (JIA): KOL insights on treatment practices and unmet needs (From Issuu)

Page 3/3

Juvenile Idiopathic Arthritis (JIA): KOL insights on treatment practices and unmet needs  

Sociable Pharma conducted in-depth primary research in the US and across Europe with seven key opinion leaders in juvenile idiopathic arthri...

Read more
Read more
Similar to
Popular now
Just for you